Pyrroloquinoline quinone drugs for treatment of cardiac injury and methods of use thereof

A method of modulating a cardioprotective signaling pathway, comprising administering, to a patient in need of cardioprotection, pyrroloquinoline quinone in an amount effective to enhance or maintain the effect of said cardioprotective signaling pathway.

A method of modulating free radical damage caused by myocardial oxidative stress, comprising administering, to a patient in need of free radical myocardial damage, pyrroloquinoline quinone in a non-toxic amount effective to inhibit free radical damage.

A method of treating or preventing myocardial hypoxic or ischemic damage in a subject, comprising administering to a subject in need thereof a non-toxic amount of an agent which modulates myocardial hypoxic or ischemic damage such that myocardial cells are protected from cell death

A method of improving coronary blood flow in a subject, comprising administering to a subject in need thereof a non-toxic amount of pyrroloquinoline quinone, such that coronary flow in said subject is improved.

A method of treating or preventing cardiac injury caused by hypoxia or ischemia in a subject, comprising administering to a subject in need thereof pyrroloquinoline quinone, such that said hypoxia or ischemic-related injury is prevented or decreased, wherein said pyrroloquinoline quinone is administered at a concentration of less than about 10 μM.

A method of treating or preventing cardiac injury caused by hypoxia or ischemia in a subject, comprising administering to a subject in need thereof pyrroloquinoline quinone, such that said hypoxia or ischemic-related injury is prevented or decreased, wherein said pyrroloquinoline quinone is administered at a non-toxic concentration.

A method of treating or preventing cardiac injury caused by hypoxia or ischemia in a subject, comprising administering to a subject in need thereof an NADPH-dependent methemoglobin reductase substrate, such that said cardiac injury is prevented or decreased.

A method of treating myocardial infarction, comprising administering to a subject in need thereof pyrroloquinoline quinone, such that said myocardial infarction is decreased or stabilized, wherein said pyrroloquinoline quinone is administered at a concentration less than about 10 μM.

A method of preventing organ damage during organ or tissue transplantation, comprising administering to an organ donor pyrroloquinoline quinone prior to or concurrent with removal of said organ, such that damage caused by reperfusion of said organ or tissue is decreased or prevented.

A method of preventing organ damage during organ or tissue transplantation, comprising contacting pyrroloquinoline quinone with one or more organs or tissues, such that damage caused by reperfusion of said organ or tissue is decreased or prevented.

A cardioprotective agent, comprising pyrroloquinoline quinone and a pharmaceutically acceptable carrier.

A kit for treating or preventing a hypoxia or ischemic-related cardiac injury, comprising in one or more containers pyrroloquinoline quinone, a pharmaceutically acceptable carrier, and instructions for use of said kit.

A method of preventing stroke in a subject suffering from heart failure, comprising treating said subject with pyrroloquinoline quinone and a pharmaceutically acceptable carrier, wherein said pyrroloquinoline quinone is administered at a concentration of less than about 10 μM.

A method of treating heart failure in a subject, comprising treating said subject with pyrroloquinoline quinone and a compound selected from the group consisting of anti-platelet drugs, anti-coagulant drugs, anti-thrombotic drugs, wherein said pyrroloquinoline quinone is administered at a concentration of less than about 10 μM

A method of preventing vascular occlusion following balloon angioplasty in a subject, comprising pre-treating said subject with pyrroloquinoline quinone and a pharmaceutically acceptable carrier.

A method of reducing or preventing migraine headaches in a subject in need thereof, comprising treating said subject with pyrroloquinoline quinone and a pharmaceutically acceptable carrier, wherein said pyrroloquinoline quinone is administered at a concentration of less than about 10 μM.

A method of preventing reperfusion injury in a subject suffering from hypothermia, comprising pre-treating said subject with pyrroloquinoline quinone and a pharmaceutically acceptable carrier.